ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIESAccrued expenses and other current liabilities consists of the following (in thousands): 

	September 30, 2023		December 31, 2022
Product revenue allowances	$	23,834	$	26,268
Product return reserves, current portion	3,312		7,789
Compensation and related benefits	7,204		11,481
Operating lease liabilities, current portion	4,861		4,744
Royalties	3,076		3,804
Professional fees	4,648		1,886
Accrued manufacturing costs	4,156		4,310
BioVectra termination fees	5,000		—
Clinical trial costs	312		5,755
Restructuring costs	617		2,751
Other	5,644		6,989
Total accrued expenses and other current liabilities	$	62,664	$	75,777

Accrued manufacturing costs includes the costs associated with the Company's commercial product Auryxia and vadadustat, a product for which the Company is seeking approval from the FDA to market in the U.S. and for which the Company recently signed a license agreement with Medice to market in Europe and other territories (see Note 4 for further details).